

# Molecular Imaging in Oncology



Edited by  
**Martin G. Pomper**  
**Juri G. Gelovani**

**informa**  
healthcare

# Molecular Imaging in Oncology



# Molecular Imaging in Oncology

Edited by

**Martin G. Pomper**

*Johns Hopkins University School of Medicine  
Baltimore, Maryland, USA*

**Juri G. Gelovani**

*MD Anderson Cancer Center  
Houston, Texas, USA*

Section Editors

**Benjamin Tsui**

*Johns Hopkins University School of Medicine  
Baltimore, Maryland, USA*

**Kathleen Gabrielson**

*Johns Hopkins University School of Medicine  
Baltimore, Maryland, USA*

**Richard Wahl**

*Johns Hopkins University School of Medicine  
Baltimore, Maryland, USA*

**S. Sam Gambhir**

*Stanford School of Medicine  
Stanford, California, USA*

**Jeff Bulte**

*Johns Hopkins University School of Medicine  
Baltimore, Maryland, USA*

**Raymond Gibson**

*Merck Research Laboratories  
West Point, Pennsylvania, USA*

**William C. Eckelman**

*Molecular Tracer, LLC  
Bethesda, Maryland, USA*

**informa**  
healthcare

---

New York London

Informa Healthcare USA, Inc.  
52 Vanderbilt Avenue  
New York, NY 10017

© 2008 by Informa Healthcare USA, Inc.  
Informa Healthcare is an Informa business

No claim to original U.S. Government works  
Printed in the United States of America on acid-free paper  
10 9 8 7 6 5 4 3 2 1

International Standard Book Number-10: 0-8493-7417-0 (Hardcover)  
International Standard Book Number-13: 978-0-8493-7417-3 (Hardcover)

This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequence of their use.

No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.

For permission to photocopy or use material electronically from this work, please access [www.copyright.com](http://www.copyright.com) (<http://www.copyright.com/>) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged.

**Trademark Notice:** Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe.

---

**Library of Congress Cataloging-in-Publication Data**

---

Molecular imaging in oncology / edited by Martin G. Pomper, Juri Gelovani.  
p. ; cm.

Includes bibliographical references and index.

ISBN-13: 978-0-8493-7417-3 (hardcover : alk. paper)

ISBN-10: 0-8493-7417-0 (hardcover : alk. paper)

1. Cancer—Imaging. 2. Molecular probes—Diagnostic use. I. Pomper, Martin G. II. Gelovani, Juri.

[DNLM: 1. Neoplasms—diagnosis. 2. Diagnostic Imaging. 3. Molecular Biology—methods. 4. Molecular Diagnostic Techniques. 5. Neoplasms—therapy. 6. Radioimmunotherapy—methods. QZ 241 M7187 2008]

RC270.3.D53M64 2008

616.99'4075—dc22

2008019422

---

**For Corporate Sales and Reprint Permissions call 212-520-2700 or write to: Sales Department,  
52 Vanderbilt Avenue, 7th floor, New York, NY 10017.**

Visit the Informa Web site at  
[www.informa.com](http://www.informa.com)

and the Informa Healthcare Web site at  
[www.informahealthcare.com](http://www.informahealthcare.com)

## Foreword

---

Molecular imaging can be traced back to France in 1896, when Henri Becquerel discovered that certain materials emitted energetic “rays,” a physical process that his graduate student, Marie Curie, later called radioactive decay. In 1929, American physicist Ernest Lawrence built the first cyclotron and was able to produce positron-emitting radionuclides. In 1931, the British physicist, Paul Dirac, had postulated the existence of positrons, based on an equation he developed in quantum mechanics. He postulated the existence of the positron as an antiparticle having the same mass as an electron but with a positive rather than negative charge. The proof of the existence of the positrons was proved in cosmic radiation by another Nobel prize winner, Carl Anderson, in 1932. That same year French physicists Irene Curie (Marie’s daughter) and Frederick Joliot (Irene’s husband) announced their discovery of artificial radioactivity. They showed that many different atoms could be made radioactive. With the Curie/Joliot publication, Lawrence immediately recognized the enormous potential value of being able to make “radioactive tracers” that made possible medically important as well as chemical and physical measurements. Subsequent pioneers recognized the great biological importance of the radioactive elements that a cyclotron could produce, including oxygen-15 and carbon-11. In the 1930s, chemist Martin Kamen, working with Lawrence, made the key discovery that the oxygen produced by the process of photosynthesis, and so important for living organisms, came from water, not from carbon dioxide, as had been previously assumed.

In the spring of 1945, the U.S. government made the decision to produce radioisotopes for civilian use. In June 1946, President Truman signed an executive order that made iodine-131 available from Oak Ridge National Laboratory to qualified physicians throughout the United States. The first shipment of carbon-14 was on August 2, 1946, to Martin Kamen at Berkeley, California. The shipment was kept secret because Kamen was falsely thought at the time to be a communist. The first announced shipment to a civilian institution was subsequently to the Barnard Free Skin and Cancer Hospital at Washington University in St. Louis. On December 7, 1946, the revolutionary announcement was made by an internist, Sam Seidlin and colleagues that radioiodine could not just ameliorate but cure metastatic cancer. According to Marshall Brucer at Oak Ridge, within days, every Congressman had heard from his constituency, and on Jan 1, 1947, the Atomic Energy Commission (AEC) took over the distribution of radioisotopes from the supersecret Manhattan District Project of World War II that had developed the atomic bomb.

In 1946, George Moore, a neurosurgeon at the University of Minnesota, used iodine-131-labeled iodofluorescein to localize brain tumors using a Geiger-Muller detector in 12 patients during surgery. In 1950 the FDA recognized iodine-131 as the first “radioactive new drug”. By 1950, 3250 publications had been published on the use of radionuclides in medicine. Molecular imaging was not accepted immediately. Marshall Brucer wrote: “Surgeons poo-pooed any thought of treating hyperthyroidism with some kind of fake iodine. Hematologists laughed at the P32 trials in the treatment of leukemias. Medical societies had no room on their agendas for radioactive isotopes.”

The public was excited by news of the use of radioiodine not only in the diagnosis of hypo- and hyperthyroidism, but in the treatment of thyroid diseases, in many patients eliminating the need for surgery. It was the first example of defining disease on the basis of a measured regional molecular process, that is, the accumulation of radioactive iodine.

“Radioisotope scanning” was the name given to imaging of the distribution of radioactive tracers in the living human body at various times after injection of a radioactive “tracer.” New “radiopharmaceuticals” were developed in the 1950s and 1960s as a means of “visualizing” previously invisible organs, such as the liver, that could not be examined effectively by conventional X-rays.

A tremendous boost to molecular imaging, then called “atomic medicine,” and subsequently “nuclear medicine” was given by a speech delivered by President Dwight Eisenhower before the 470th plenary meeting of the United Nations in New York on December 8, 1953. He said:

“The more important responsibility of a new (atomic energy) agency would be to devise methods whereby fissionable material would be allocated to serve the peaceful pursuits of mankind. Experts would be mobilized to apply atomic energy to the needs of agriculture, medicine and other peaceful activities. I would be prepared to submit to the Congress of the United States, and with every expectation of approval, any such plan that would, first, encourage world-wide investigation into the most effective peacetime uses of fissionable material, and with the certainty that the investigators had all the material needed for the conducting of all experiments that were appropriate.”

President Eisenhower’s speech led to the creation of the International Atomic Energy Agency (IAEA), which made possible research with radioactive tracers all over the world. The types of studies include measurement of regional blood flow to organs and lesions, measurement of the regional bioenergetics, and molecular processes involved in intercellular communication.

Since the 1950s molecular imaging has encompassed much more than the peaceful use of radioactivity. Although radiopharmaceutical-based techniques tend to dominate clinical molecular imaging presently, molecular imaging is not really about any specific modality. It is about uncovering physiology noninvasively by probing specific cellular and molecular processes in vivo. What has made molecular imaging so exciting now is the introduction of efficient, high-sensitivity devices for preclinical (animal model) as well as clinical imaging. Hybrid imaging devices, which combine the high resolution of anatomic imaging with the physiologic techniques, are also becoming standard in clinical practice and enable determination of a metabolic or receptor defect with pinpoint accuracy within minutes. Increasingly relevant imaging targets are being uncovered due to protein arrays and high-throughput methods by which to interrogate human biopsy specimens. Mice that can be genetically manipulated not only help validate those targets but also provide excellent models in which to test new molecular imaging probes. The introduction of current molecular biological techniques—as they evolve in real time—to imaging science will only make molecular imaging increasingly relevant to study physiology and disease in the coming years.

Oncology is perhaps the most fruitful domain of molecular imaging at present, particularly because of the information provided in measuring the energy supply of lesions, the abundance of unexploited tumor markers, and intra- and intercellular

communication pathways amenable to imaging. This book describes the development, principles, and uses of molecular imaging in answering the questions raised in the practice of medicine, with an emphasis on oncology: (1) What is the problem? (2) Where is the problem? (3) What is going to happen? (4) What is the best course of action and treatment? (5) Is the treatment effective? A graded approach is taken whereby there will be a brief introduction to basic principles in biology and molecular imaging, then to the modalities available on through clinical molecular imaging of cancer. Medicine has moved from whole body to organs to tissues to cells and now to molecules. We are indeed in a revolutionary time in the history of medicine.

*Henry N. Wagner, Jr., MD*





# Preface

---

Although a relatively new aspect of imaging science and practice, molecular imaging is beginning to make its presence felt. It has done so because it involves the collaboration between two rapidly evolving fields, namely, molecular biology—including genomics, proteomics, and the use of transgenic animal models—and high-sensitivity imaging devices to probe cellular and molecular phenomena in vivo. Those two fields are powerful in their own right, but together they can generate considerable new knowledge about normal cellular processes and disease and, in particular, cancer.

This volume is dedicated to the molecular imaging of cancer, taking a graded approach to the subject by first introducing concepts of basic molecular biology (sect. 1) and the operation of the various imaging modalities (sect. 2). We felt it was necessary for the reader to understand the challenges in the development of imaging probes (sect. 3) and in performing imaging in animal models—the mainstay of current molecular imaging research (sect. 4). More directly germane to the molecular imaging of cancer are chapters dedicated specifically to molecular-genetic imaging (sect. 5), imaging cellular migration and other processes (sect. 6) and clinical translation (sect. 7), where examples from several key clinical challenges are provided (sect. 8). The final chapters highlight imaging in anticancer drug development and how to move into the future through collaboration with industry and the government (sect. 9).

Although molecular imaging is evolving rapidly, due to the incorporation of nanobiotechnology, microfluidics, and other rapidly advancing fields, we have tried to maintain relevance for the practicing clinician—who will be the ultimate arbiter as to whether molecular imaging will actually prove useful for and adopted into clinical practice. Nevertheless, sufficient detail is provided so that graduate students and established practitioners in allied fields, e.g., chemistry, imaging physics, and cell biology, can become acquainted with molecular imaging in cancer and begin incorporating imaging beneficially into their work, likely generating new ideas previously unseen by dedicated imaging scientists.

*Martin Pomper, MD, PhD*



# Contents

---

<i>Foreword</i> .....	<i>iii</i>
<i>Preface</i> .....	<i>vii</i>
<i>Contributors</i> .....	<i>xiii</i>
<i>A Word on “Molecular Imaging”</i> .....	<i>xix</i>

## **Foundations (Sanjiv Sam Gambhir)**

<b>1. Tumor Biology</b> .....	<b>1</b>
<i>Surajit Dhara</i>	
<b>2. Introduction to Molecular Biology</b> .....	<b>29</b>
<i>Julie Heroux and Ahmed M. Gharib</i>	
<b>3. Methods in Molecular Biology</b> .....	<b>43</b>
<i>Julie Heroux and Ahmed M. Gharib</i>	
<b>4. The Analysis of Complex Data Sets: Challenges and Opportunities</b> .....	<b>55</b>
<i>Edward H. Herskovits</i>	

## **Instrumentation (Benjamin M. W. Tsui)**

<b>5. Molecular PET Instrumentation and Imaging Techniques</b> .....	<b>67</b>
<i>Roger Lecomte</i>	
<b>6. Molecular SPECT Imaging Instrumentation and Techniques</b> .....	<b>93</b>
<i>Benjamin M. W. Tsui, Yuchuan Wang, and Seng Peng Mok</i>	
<b>7. Ultrasound Instrumentation and Techniques</b> .....	<b>109</b>
<i>Paul A. Dayton and Mark A. Borden</i>	
<b>8. Oncological Applications of MR Spectroscopy</b> .....	<b>121</b>
<i>Marie-France Penet, Kristine Glunde, Michael A. Jacobs, Noriko Mori, Dmitri Artemov, and Zaver M. Bhujwala</i>	

<b>9. Physiological and Functional Imaging with CT: Techniques and Applications .....</b>	<b>139</b>
<i>Ting-Yim Lee, Eugene Wong, Errol Stewart, Jim Xuan, Glenn Bauman, and Peter Gabra</i>	
<b>10. Multimodality Imaging Instrumentation and Techniques.....</b>	<b>157</b>
<i>Douglas J. Wagenaar and Bradley E. Patt</i>	
<b>Probe Design (William C. Eckelman)</b>	
<b>11. Targeted Agents for MRI.....</b>	<b>169</b>
<i>Dmitri Artemov</i>	
<b>12. High-Throughput Screening for Probe Development .....</b>	<b>179</b>
<i>Kimberly A. Kelly, Fred Reynolds, and Kelly R. Kristof</i>	
<b>13. Radiopharmaceuticals for SPECT.....</b>	<b>189</b>
<i>Ronnie C. Mease</i>	
<b>14. Radionuclides for Therapy .....</b>	<b>217</b>
<i>George Sgouros</i>	
<b>15. CEST Contrast Agents.....</b>	<b>227</b>
<i>Jason M. Zhao, Assaf A. Gilad, Michael T. McMahon, Jeff W. M. Bulte, and Peter C. M. van Zijl,</i>	
<b>16. Optical Imaging Probes.....</b>	<b>245</b>
<i>Alexei A. Bogdanov Jr.</i>	
<b>17. Nanoparticle-Based Molecular Imaging in Living Subjects .....</b>	<b>261</b>
<i>Bryan Ronain Smith and Sanjiv Sam Gambhir</i>	
<b>18. Long-Lived and Unconventional PET Radionuclides.....</b>	<b>283</b>
<i>Jason S. Lewis, Rajendra K. Singh, and Michael J. Welch</i>	
<b>19. Design of New Imaging Agents Using Positron-Emitting Radionuclides as the Reporter.....</b>	<b>293</b>
<i>William C. Eckelman</i>	
<b>20. Targeted Radiolabeled Receptor-Avid Peptides .....</b>	<b>307</b>
<i>Wynn A. Volkert</i>	
<b>21. Targeted Ultrasound Contrast Agents.....</b>	<b>329</b>
<i>Mark A. Borden and Paul A. Dayton</i>	
<b>Small Animal Imaging (Kathleen Gabrielson)</b>	
<b>22. Quantification in Small-Animal PET and SPECT Imaging.....</b>	<b>345</b>
<i>Paul D. Acton</i>	
<b>23. In Vivo Imaging Mouse Models of Breast Cancer .....</b>	<b>357</b>
<i>Kathleen Gabrielson, Teresa Southard, Yi Xu, Frank C. Marini, Brett M. Hall, Robert D. Cardiff, and Venu Raman</i>	
<b>24. Basics of Small Animal Handling for In Vivo Imaging .....</b>	<b>377</b>
<i>Laurence W. Hedlund and Tracy L. Gluckman</i>	
<b>Molecular-genetic Imaging (Juri G. Gelovani)</b>	
<b>25. Imaging Cellular Networks and Protein-Protein Interactions In Vivo....</b>	<b>391</b>
<i>Snehal Naik, Britney L. Moss, David Piwnica-Worms, and Andrea Pichler-Wallace</i>	

<b>26. Novel Reporter Probes for <i>HSV1-tk</i> Gene Expression</b> .....	<b>405</b>
<i>Mian M. Alauddin and Juri G. Gelovani</i>	
<b>27. Clinical Potential of Gene Expression Imaging</b> .....	<b>429</b>
<i>Vikas Kundra</i>	
<b>28. Molecular-Genetic Imaging</b> .....	<b>443</b>
<i>Yannic Waerzeggers, Alexandra Winkeler, and Andreas H. Jacobs</i>	
<b>Cellular Processes (Jeff W. M. Bulte)</b>	
<b>29. Imaging Angiogenesis</b> .....	<b>469</b>
<i>Ambros J. Beer and Markus Schwaiger</i>	
<b>30. Imaging Apoptosis</b> .....	<b>493</b>
<i>T. Z. Belhocine</i>	
<b>31. Imaging Cell Trafficking with MR Imaging</b> .....	<b>503</b>
<i>Assaf A. Gilad, Piotr Walczak, Michael T. McMahon, and Jeff W. M. Bulte</i>	
<b>32. General Considerations for Labeling and Imaging of Cells</b> .....	<b>513</b>
<i>Hisataka Kobayashi</i>	
<b>33. Molecular Imaging of the Extracellular Matrix and Lymphatic Phenomena in Tumors</b> .....	<b>523</b>
<i>Arvind P. Pathak and Zaver M. Bhujwalla</i>	
<b>34. Nuclear Imaging of Adoptive Cell Therapies</b> .....	<b>531</b>
<i>Vladimir Ponomarev</i>	
<b>35. Optical Techniques for Imaging of Cell Trafficking</b> .....	<b>545</b>
<i>Khalid Shah</i>	
<b>Clinical Translation (Richard L. Wahl)</b>	
<b>36. Radiopharmaceutical Therapy of Cancer</b> .....	<b>557</b>
<i>Daniel A. Pryma and Chaitanya R. Divgi</i>	
<b>37. Radioimmunodetection of Cancer: The Next Dimension</b> .....	<b>571</b>
<i>David M. Goldenberg and Robert M. Sharkey</i>	
<b>38. Diffusion Magnetic Resonance Imaging for Cancer Treatment Response Assessment</b> .....	<b>585</b>
<i>Brian D. Ross, Kuei C. Lee, Craig J. Galban, Charles R. Meyer, Thomas L. Chenevert, and Alnawaz Rehemtulla</i>	
<b>39. Molecular Imaging of Breast Cancer</b> .....	<b>593</b>
<i>Jean H. Lee, Lavanya Sundararajan, William B. Eubank, and David A. Mankoff</i>	
<b>40. FDG PET/CT Imaging: Clinical Uses and Opportunities</b> .....	<b>605</b>
<i>Oleg M. Teytelboym and Richard L. Wahl</i>	
<b>41. Molecular Imaging in Prostate Cancer</b> .....	<b>623</b>
<i>Steve Y. Cho and Martin G. Pomper</i>	
<b>Opportunities from Industry/Government (Raymond E. Gibson)</b>	
<b>42. Anticancer Drug Development with Optical Imaging</b> .....	<b>645</b>
<i>Bohumil Bednar, Guo-Jun Zhang, and Cyrille Sur</i>	

<b>43. Drug Development with Radiopharmaceuticals .....</b>	<b>659</b>
<i>Henry F. VanBrocklin</i>	
<b>44. NIH Funding Sources for Molecular Imaging in Oncology .....</b>	<b>671</b>
<i>Anne E. Menkens, Barbara Y. Croft, and Daniel C. Sullivan</i>	
<b>45. Drug Development with Magnetic Resonance Imaging .....</b>	<b>677</b>
<i>Jeffrey L. Evelhoch</i>	
<b>46. Industrial-Academic Collaboration .....</b>	<b>687</b>
<i>Raymond E. Gibson and Cynthia J. Zarsky</i>	
<b>47. The Future of Molecular Imaging .....</b>	<b>693</b>
<i>Steven M. Larson</i>	
<i>Index .....</i>	<i>705</i>

# Contributors

---

**Paul D. Acton** Johnson & Johnson Pharmaceutical R&D, Spring House, Philadelphia, Pennsylvania, U.S.A.

**Mian M. Alauddin** Department of Experimental Diagnostic Imaging, Center for Advanced Biomedical Imaging Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.

**Dmitri Artemov** JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Glenn Bauman** Department of Oncology, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada

**Bohumil Bednar** Imaging Department, Merck Research Laboratories, Merck & Co, Inc., West Point, Pennsylvania, U.S.A.

**Ambros J. Beer** Department of Nuclear Medicine, Technische Universität München, Munich, Germany

**T. Z. Belhocine** Department of Diagnostic Radiology and Nuclear Medicine, St. Joseph's Hospital, London, Ontario, Canada

**Zaver M. Bhujwala** JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Alexei A. Bogdanov Jr.** Departments of Radiology and Cell Biology, University of Massachusetts Medical School, Worcester, Massachusetts, U.S.A.

**Mark A. Borden** Department of Chemical Engineering, Columbia University, New York, New York, U.S.A.

**Jeff W. M. Bulte** Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, and Cellular Imaging Section, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.



**Robert D. Cardiff**    Department of Pathology, School of Medicine, University of California, Davis, California, U.S.A.

**Thomas L. Chenevert**    Department of Radiology, University of Michigan, Ann Arbor, Michigan, U.S.A.

**Steve Y. Cho**    Division of Nuclear Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Barbara Y. Croft**    Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.

**Paul A. Dayton**    Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, North Carolina, U.S.A.

**Surajit Dhara**    Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Chaitanya R. Divgi**    Department of Radiology, Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.

**William C. Eckelman**    Molecular Tracer LLC, Bethesda, Maryland, U.S.A.

**William B. Eubank**    Department of Radiology, University of Washington and Puget Sound VA Medical Center, Seattle, Washington, U.S.A.

**Jeffrey L. Evelhoch**    Imaging Sciences, Medical Sciences, Amgen, Inc., Thousand Oaks, California, U.S.A.

**Peter Gabra**    Department of Medical Biophysics, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada

**Kathleen Gabrielson**    Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Craig J. Galban**    Department of Radiology, University of Michigan, Ann Arbor, Michigan, U.S.A.

**Sanjiv Sam Gambhir**    Molecular Imaging Program at Stanford, Department of Radiology, Stanford School of Medicine, Stanford, California, U.S.A.

**Juri G. Gelovani**    Department of Experimental Diagnostic Imaging, Center for Advanced Biomedical Imaging Research, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.

**Ahmed M. Gharib**    Diagnostic Radiology Department, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, U.S.A.

**Raymond E. Gibson**    Imaging Department, Merck Research Laboratories, West Point, Pennsylvania, U.S.A.

**Assaf A. Gilad**    Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, and Cellular Imaging Section, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Tracy L. Gluckman**    Department of Molecular and Comparative Pathobiology, Johns Hopkins University, Baltimore, Maryland, U.S.A.

**Kristine Glunde** JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**David M. Goldenberg** Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, U.S.A.

**Brett M. Hall** Department of Pediatrics, Columbus Children's Research Institute, The Ohio State University School of Medicine, Columbus, Ohio, U.S.A.

**Laurence W. Hedlund** Center for In Vivo Microscopy, Department of Radiology, Duke University Medical Center, Durham, North Carolina, U.S.A.

**Julie Heroux** Diagnostic Radiology Department, National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health (NIH), Bethesda, Maryland, U.S.A.

**Edward H. Herskovits** Department of Radiology, University of Pennsylvania, Philadelphia, U.S.A.

**Andreas H. Jacobs** Laboratory for Gene Therapy and Molecular Imaging at the Max Planck Institute for Neurological Research with Klaus-Joachim Zülch-Laboratories of the Max Planck Society and the Faculty of Medicine of the University of Cologne, Cologne, Germany

**Michael A. Jacobs** JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Kimberly A. Kelly** Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, U.S.A.

**Hisataka Kobayashi** Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, U.S.A.

**Kelly R. Kristof** Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, U.S.A.

**Vikas Kundra** Departments of Diagnostic Radiology and Experimental Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.

**Steven M. Larson** Memorial Sloan-Kettering Cancer Center, New York, New York, U.S.A.

**Roger Lecomte** Sherbrooke Molecular Imaging Center, Department of Nuclear Medicine and Radiobiology, Université de Sherbrooke, Sherbrooke, Quebec, Canada

**Kuei C. Lee** Department of Radiology, University of Michigan, Ann Arbor, Michigan, U.S.A.

**Jean H. Lee** Department of Radiology, University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, U.S.A.

**Ting-Yim Lee** Imaging Program, Lawson Health Research Institute; Imaging Research Laboratories, Robarts Research Institute; and Departments of Medical Imaging and Medical Biophysics, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada

**Jason S. Lewis** Department of Radiology, Memorial-Sloan Kettering Cancer Center, New York, New York, U.S.A.

**David A. Mankoff** Departments of Radiology and Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, U.S.A.

**Frank C. Marini**    M.D. Anderson Cancer Center, University of Texas, Houston, Texas, U.S.A.

**Michael T. McMahon**    Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. and F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, U.S.A.

**Ronnie C. Mease**    Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Anne E. Menkens**    Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.

**Charles R. Meyer**    Department of Radiology, University of Michigan, Ann Arbor, Michigan, U.S.A.

**Seng Peng Mok**    Department of Radiology, Johns Hopkins University, Baltimore, Maryland, U.S.A.

**Noriko Mori**    JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Britney L. Moss**    Molecular Imaging Center, Mallinckrodt Institute of Radiology and Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri, U.S.A.

**Snehal Naik**    Molecular Imaging Center, Mallinckrodt Institute of Radiology and Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri, U.S.A.

**Arvind P. Pathak**    JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, and Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Bradley E. Patt**    Gamma Medica-Ideas, Inc., Northridge, California, U.S.A.

**Marie-France Penet**    JHU ICMIC Program, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**David Piwnica-Worms**    Molecular Imaging Center, Mallinckrodt Institute of Radiology and Department of Molecular Biology and Pharmacology, Washington University School of Medicine, St. Louis, Missouri, U.S.A.

**Andrea Pichler-Wallace**    Molecular Imaging Center, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, Missouri, U.S.A.

**Martin G. Pomper**    Division of NeuroRadiology, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Vladimir Ponomarev**    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York, U.S.A.

**Daniel A. Pryma**    Department of Radiology, Division of Nuclear Medicine and Clinical Molecular Imaging, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.

**Venu Raman** Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Alnawaz Rehemtulla** Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan, U.S.A.

**Fred Reynolds** Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, U.S.A.

**Brian D. Ross** Department of Radiology, University of Michigan, Ann Arbor, Michigan, U.S.A.

**Markus Schwaiger** Department of Nuclear Medicine, Technische Universität München, Munich, Germany

**George Sgouros** Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Khalid Shah** Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, U.S.A.

**Robert M. Sharkey** Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, New Jersey, U.S.A.

**Rajendra K. Singh** Department of Radiology, Washington University School of Medicine, St. Louis, Missouri, U.S.A.

**Bryan Ronain Smith** Molecular Imaging Program at Stanford, Department of Radiology, Stanford School of Medicine, Stanford, California, U.S.A.

**Teresa Southard** Department of Molecular and Comparative Pathobiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A.

**Errol Stewart** Department of Medical Biophysics, Schulich School of Medicine & Dentistry, The University of Western Ontario, London, Ontario, Canada

**Daniel C. Sullivan** Cancer Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.

**Lavanya Sundararajan** Department of Medicine, University of Washington and Seattle Cancer Care Alliance, Seattle, Washington, U.S.A.

**Cyrille Sur** Imaging Department, Merck Research Laboratories, Merck & Co, Inc., West Point, Pennsylvania, U.S.A.

**Oleg M. Teytelboym** Division of Nuclear Medicine, Department of Radiology and Radiological Sciences, Johns Hopkins University, Baltimore, Maryland, U.S.A.

**Benjamin M. W. Tsui** Department of Radiology, Johns Hopkins University, Baltimore, Maryland, U.S.A.

**Peter C. M. van Zijl** Russell H. Morgan Department of Radiology and Radiological Science, Division of MR Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. and F.M. Kirby Research Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, Maryland, U.S.A.

**Henry F. VanBrocklin** Department of Radiology and Biomedical Imaging, University of California, San Francisco, California, U.S.A.

**Wynn A. Volkert** Department of Radiology and the Radiopharmaceutical Sciences Institute, University of Missouri and H.S. Truman Memorial Veterans Administration Hospital, Columbia, Missouri, U.S.A.